Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
PR95768
LONDON, April 29, 2022 /PRNewswire=KYODO JBN/ --
Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any
transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement
issued today indicating that Opiant Pharmaceuticals and Hikma have entered into
a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in
Europe and the UK.
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:
549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the United
States (US), the Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into innovative
solutions that transform people's lives. We're committed to our customers, and
the people they care for, and by thinking creatively and acting practically, we
provide them with a broad range of branded and non-branded generic medicines.
Together, our 8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner, and through
our venture capital arm, are helping bring innovative health technologies to
people around the world. For more information, please visit: www.hikma.com
(C) 2022 Hikma Pharmaceuticals PLC. All rights reserved.
Source: Hikma Pharmaceuticals PLC
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
